Semaglutide May Double nAMD Risk in Older Adults: Study

A widely used diabetes and weight-loss medicine, semaglutide—sold under the brand names Ozempic and Wegovy—is now under closer review following a large new study on semaglutide vision loss risks in older adults. Researchers from the University of Toronto have found that older adults with diabetes who took semaglutide had more than twice the risk of developing neovascular age-related macular degeneration (nAMD), a serious eye disease leading to rapid central vision loss.

Understanding Neovascular Age-Related Macular Degeneration (nAMD)

Age-related macular degeneration (AMD) is one of the leading causes of vision loss in older adults, particularly in Western countries. It has two main types: dry AMD, which is more common and progresses slowly, and wet AMD, also known as neovascular AMD (nAMD), which is less common but far more aggressive.

In nAMD, abnormal blood vessels grow underneath the retina at the back of the eye. These fragile vessels can leak blood or fluid, damaging the macula—the small central area of the retina responsible for sharp, detailed vision used in reading, driving, and recognizing faces. Without prompt intervention, this leads to permanent central vision loss.

Why nAMD Matters for Older Adults with Diabetes

Diabetes already heightens the risk of various eye complications, including diabetic retinopathy and macular edema. The macula's vulnerability in nAMD overlaps with diabetic changes, making older patients on glucose-lowering therapies particularly susceptible. Early detection through comprehensive dilated eye exams is crucial, as treatments like anti-VEGF injections can slow progression and preserve vision.

How Semaglutide Works: GLP-1 Receptor Agonists Explained

Semaglutide belongs to the class of GLP-1 receptor agonists, which mimic the glucagon-like peptide-1 hormone. These drugs lower blood sugar in type 2 diabetes by enhancing insulin release, slowing gastric emptying, and reducing appetite. Beyond glycemic control, semaglutide has demonstrated cardiovascular benefits, reducing heart disease risk in trials like SUSTAIN 6 and PIONEER 6.

Its weight-loss effects have fueled off-label use for obesity, even in non-diabetics. However, earlier trials such as SUSTAIN 6 and PIONEER 6 noted higher rates of diabetic eye problems in semaglutide users compared to placebo. Rare optic nerve damage reports exist, though some lab studies hinted at protective eye effects—creating mixed signals on ocular safety.

Key Findings from the University of Toronto Study

Published in JAMA Ophthalmology, this observational study analyzed health records from 139,002 adults aged 66 and older in Ontario, Canada, from 2020 to 2023. All had diabetes; 46,334 had taken semaglutide or similar GLP-1 drugs for at least six months, while others had not.

Using advanced statistical adjustments for confounders, researchers found:

• GLP-1 users were more than twice as likely to be diagnosed with nAMD.
• Risk escalated with duration: more than three times higher after over 30 months of use.
• Exacerbating factors included older age and history of stroke or cerebral vascular issues, suggesting vascular vulnerabilities amplify the association.

"The risk appeared to increase with longer use. Patients who had been taking the medication for more than 30 months were more than three times as likely to develop the condition." — Study summary from JAMA Ophthalmology.

Study Limitations and Causation Caveats

Scientists emphasize it's premature to claim semaglutide directly causes nAMD. The link may stem from diabetes severity, unmeasured confounders, or shared vascular pathways. Diabetes promotes retinal neovascularization, and GLP-1s' effects on blood flow or inflammation warrant further mechanistic studies. Randomized controlled trials are needed for causality.

Clinical Implications: Who Should Be Monitored?

As semaglutide's popularity surges for diabetes management and weight loss—used by millions, including many older adults at baseline AMD risk—eye health vigilance is paramount. Researchers recommend:

• Regular eye exams for all semaglutide users, especially after one year of use.
• Closer monitoring for those over 66, with long-term use (>30 months), or vascular history (e.g., stroke).
• Discuss symptoms like blurred central vision, distorted lines (Amsler grid test at home), or dark spots with your ophthalmologist promptly.

Patients can track subtle vision changes or medication adherence using apps like Shotlee, which logs symptoms and schedules alongside metabolic health metrics.

Safety Profile and Side Effects Context

While GLP-1s like semaglutide offer proven benefits for weight, glucose, and heart health, gastrointestinal issues dominate common side effects. Ocular risks, though rarer, align with prior signals. No dosage specifics altered outcomes here, but standard weekly injections (e.g., 0.25-2.4 mg) apply. Always weigh benefits against risks with your healthcare provider.

Comparisons to Other Therapies

Other GLP-1s (e.g., liraglutide) share class effects, but this study focused on semaglutide. Alternatives like SGLT2 inhibitors or DPP-4 inhibitors show less weight loss but potentially fewer eye signals. For obesity, lifestyle interventions or bariatric options remain non-pharmacologic baselines. Discuss personalized risks via tools like the ASCVD calculator alongside eye-specific assessments.

Key Takeaways for Patients and Providers

• Semaglutide users over 66 with diabetes face >2x nAMD risk, rising to >3x with prolonged use.
• Not proven causal—diabetes and vascular factors contribute.
• Prioritize annual (or more frequent) ophthalmology visits; early anti-VEGF therapy can mitigate damage.
• Balance GLP-1 benefits for heart, weight, and diabetes against emerging long-term signals.

Future Research Directions

Longitudinal studies and mechanistic trials will clarify if GLP-1s promote retinal angiogenesis or if detection bias plays a role. As usage expands, pharmacovigilance via real-world data like Ontario's will guide updates to prescribing guidelines.

Conclusion: Actionable Insights for Metabolic Health

This JAMA Ophthalmology study underscores the need for holistic monitoring in semaglutide therapy. While benefits for type 2 diabetes, obesity, and cardiovascular risk persist, older adults should integrate eye health into their care plan. Consult your doctor about baseline and follow-up exams to safeguard vision amid metabolic gains. Stay informed on evolving GLP-1 research for optimal outcomes.